Melanoma Institute Australia at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Melanoma Institute Australia takes part in 3 sessions at ESMO 2026 in Madrid. Its program centres on early and resected melanoma, from the surgeon's role in managing lymph nodes to treatment before or after surgery. It presents a phase 3 trial of an mRNA-based individualised neoantigen therapy plus pembrolizumab, against pembrolizumab alone, after surgery for stage IIB to IV melanoma.
| Organization | ESMO 2026 Attendance |
|---|---|
Melanoma Institute Australia Wollstonecraft, Australia | |
Nonprofit melanoma research and treatment centre in Sydney, Australia, affiliated with the University of Sydney. | Talk Sat Oct 24 15:10–15:35 Lymph nodes under the knife Melanoma & skin cancers Abstract Sat Oct 24 16:30–16:42 LBA1 - INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL) Lung & thoracic cancersMelanoma & skin cancersGenitourinary cancers Satellite Sun Oct 25 19:20–19:40 Neoadjuvant or Adjuvant Therapies for Stage II Melanoma Melanoma & skin cancers Satellite Sun Oct 25 19:40–20:00 Audience Q&A and Panel Discussion Melanoma & skin cancers |
Instantly find 20 buyers from Melanoma Institute Australia
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction